NiKang Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 41

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 26

NiKang Therapeutics General Information

Description

Operator of a biotechnology company intended to discover and develop innovative small-molecule oncology medicines. The company focuses on combating cancer and helping patients with unmet medical needs through deep insights into disease biology and molecular pathways, enabling healthcare providers to treat their patients and improve their lives.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 200 Powder Mill Road
  • Building E500
  • Wilmington, DE 19803
  • United States
+1 (302)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 200 Powder Mill Road
  • Building E500
  • Wilmington, DE 19803
  • United States
+1 (302)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NiKang Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 19-May-2021 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 09-Sep-2020 Completed Clinical Trials - General
2. Debt - PPP 28-Apr-2020 $236K $10M Completed Clinical Trials - General
1. Early Stage VC (Series A) 04-Dec-2017 $10M $10M Completed Startup
To view NiKang Therapeutics’s complete valuation and funding history, request access »

NiKang Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B2
Series B1 16,071,426 $0.000100 $2.8 $2.8 1x $2.8 20.49%
Series A 10,000,000 $0.000100 $1 $1 1x $1 12.75%
To view NiKang Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NiKang Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to discover and develop innovative small-molecule oncology medicines. The c
Drug Discovery
Wilmington, DE
41 As of 2023

San Diego, CA
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NiKang Therapeutics Competitors (3)

One of NiKang Therapeutics’s 3 competitors is Vividion Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vividion Therapeutics Formerly VC-backed San Diego, CA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Cybrexa Therapeutics Venture Capital-Backed New Haven, CT
You’re viewing 3 of 3 competitors. Get the full list »

NiKang Therapeutics Patents

NiKang Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026212994-A1 Bifunctional compounds containing multi substituted alkylsulfonyl linker for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway Pending 31-Mar-2025
WO-2026198338-A1 Bifunctional compounds containing substituted alkylsulfonyl linker moiety for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway Pending 19-Mar-2025
WO-2026011344-A1 Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway Pending 10-Jul-2024
WO-2025240536-A1 Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway Pending 15-May-2024
WO-2025235261-A1 Bifunctional compounds containing 2,4,5-substituted pyrimidine derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway Pending 07-May-2024 A61K31/506
To view NiKang Therapeutics’s complete patent history, request access »

NiKang Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NiKang Therapeutics Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ally Bridge Group Growth/Expansion Minority
BlackRock Asset Manager Minority
Cormorant Asset Management PE/Buyout Minority
EcoR1 Capital Venture Capital Minority
Invus (Private Equity) PE/Buyout Minority
You’re viewing 5 of 26 investors. Get the full list »

NiKang Therapeutics FAQs

  • When was NiKang Therapeutics founded?

    NiKang Therapeutics was founded in 2017.

  • Where is NiKang Therapeutics headquartered?

    NiKang Therapeutics is headquartered in Wilmington, DE.

  • What is the size of NiKang Therapeutics?

    NiKang Therapeutics has 41 total employees.

  • What industry is NiKang Therapeutics in?

    NiKang Therapeutics’s primary industry is Drug Discovery.

  • Is NiKang Therapeutics a private or public company?

    NiKang Therapeutics is a Private company.

  • What is NiKang Therapeutics’s current revenue?

    The current revenue for NiKang Therapeutics is .

  • How much funding has NiKang Therapeutics raised over time?

    NiKang Therapeutics has raised $260M.

  • Who are NiKang Therapeutics’s investors?

    Ally Bridge Group, BlackRock, Cormorant Asset Management, EcoR1 Capital, and Invus (Private Equity) are 5 of 26 investors who have invested in NiKang Therapeutics.

  • Who are NiKang Therapeutics’s competitors?

    Vividion Therapeutics, Inovio Pharmaceuticals, and Cybrexa Therapeutics are competitors of NiKang Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process